Holen Sie sich die Stockscreener-App
37.23
0.11%
-0.035
Schlusskurs vom Vortag:
$37.27
Offen:
$37.1
24-Stunden-Volumen:
1.33M
Relative Volume:
0.35
Marktkapitalisierung:
$15.70B
Einnahmen:
$2.26B
Nettoeinkommen (Verlust:
$1.09B
KGV:
15.89
EPS:
2.3431
Netto-Cashflow:
$2.70B
1W Leistung:
+3.39%
1M Leistung:
+3.33%
6M Leistung:
+17.85%
1J Leistung:
+30.45%
1-Tages-Spanne:
$36.84
$37.50
1-Wochen-Bereich:
$36.00
$37.56
52-Wochen-Spanne:
$24.05
$37.56
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
37.25 | 15.62B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.96 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.42 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
342.46 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
604.83 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.86 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Pacific Capital Partners Ltd Takes Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Envestnet Asset Management Inc. Boosts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc stock volume spike explainedScalable Portfolio Growth Suggestions Released - metal.it
Published on: 2025-07-29 22:21:39 - metal.it
Baillie Gifford & Co. Decreases Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Machine Learning Models Forecast Royalty Pharma plc UptickConsistent Income Focused Trade List Analyzed - metal.it
Can Royalty Pharma plc Regain Momentum After BreakdownCommunity Shared Smart Money Signals Show Movement - metal.it
Bollinger Bands Expand on Royalty Pharma plc — Volatility AheadWeekly Chart Analysis With Entry Advice Provided - metal.it
Royalty Pharma stock hits 52-week high at 36.89 USD - Investing.com Australia
Why is Royalty Pharma plc stock attracting strong analyst attentionExceptional stock performance - jammulinksnews.com
Is it the right time to buy Royalty Pharma plc stockSuperior portfolio returns - jammulinksnews.com
Ridgewood Investments LLC Decreases Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What makes Royalty Pharma plc stock price move sharplyInvest confidently with real-time updates - jammulinksnews.com
Mediolanum International Funds Ltd Lowers Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Position Trimmed by Allianz Asset Management GmbH - MarketBeat
Cwm LLC Increases Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What is Royalty Pharma plc company’s growth strategyUnmatched profit growth - jammulinksnews.com
How does Royalty Pharma plc compare to its industry peersCapitalize on strong market momentum - jammulinksnews.com
Is Royalty Pharma plc stock overvalued or undervaluedUnlock powerful trading signals and alerts - jammulinksnews.com
Published on: 2025-07-28 08:51:02 - jammulinksnews.com
What are the latest earnings results for Royalty Pharma plcMaximize your portfolio’s earning potential - jammulinksnews.com
When is Royalty Pharma plc stock expected to show significant growthDynamic profit opportunities - jammulinksnews.com
What markets is GCLWW expanding into Is Royalty Pharma plc stock a good long term investment optionGet daily updates on promising stocks - jammulinksnews.com
Vestor Capital LLC Takes $12.60 Million Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month HighHere's What Happened - MarketBeat
Royalty Pharma: A High-Margin, Earnings-Driven Opportunity in the Biopharma Royalty Space - AInvest
What analysts say about Royalty Pharma plc stockFree Wealth Planning Blueprint - PrintWeekIndia
Royalty Pharma plc Stock Analysis and ForecastSuperior portfolio returns - PrintWeekIndia
Is Royalty Pharma plc a good long term investmentDouble-digit growth - Autocar Professional
Royalty Pharma (NASDAQ:RPRX) Given New $42.00 Price Target at Citigroup - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Holdings Lifted by Los Angeles Capital Management LLC - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by New York State Common Retirement Fund - MarketBeat
Royalty Pharma Plc's (NASDAQ:RPRX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - 富途牛牛
Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
Edgestream Partners L.P. Makes New $659,000 Investment in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What drives Royalty Pharma plc stock pricePhenomenal wealth increase - Autocar Professional
Citigroup maintains Buy rating, raises PT for Royalty Pharma to $42. - AInvest
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):